Actively Recruiting
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Led by Xencor, Inc. · Updated on 2026-03-05
307
Participants Needed
23
Research Sites
337 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
CONDITIONS
Official Title
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects must have measurable disease by RECIST 1.1 criteria as assessed by the local investigator
- Subjects must have relapsed and refractory clear cell renal cell carcinoma (ccRCC), papillary RCC (pRCC), non-small cell lung cancer (NSCLC), or colorectal cancer (CRC) with disease progression on standard therapies
- ECOG performance status must be 0 or 1
- Adequate tumor sample must be available (slides or archival FFPE blocks)
You will not qualify if you...
- Prior treatment with investigational anti-ENPP3/CD203c therapy
- History of serious allergic or anaphylactic/hypersensitivity reaction to monoclonal antibody therapy
- Received systemic antineoplastic therapy within 5 half-lives before first dose
- Failure to recover from significant toxicity related to previous anticancer treatment
- Known active central nervous system metastases or carcinomatous meningitis (stable treated brain metastases allowed)
- Active known autoimmune disease, except specified exceptions managed without systemic therapy
- Serious infection requiring IV anti-infective treatment within 14 days before first dose
- Known additional malignancy that is progressing or required active treatment within past 2 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 23 locations
1
Xencor Investigative Site
Phoenix, Arizona, United States, 85054
Actively Recruiting
2
Xencor Investigative Site
Duarte, California, United States, 91010
Actively Recruiting
3
Xencor Investigative Site
Sacramento, California, United States, 95817
Actively Recruiting
4
Xencor Investigative Site
New Haven, Connecticut, United States, 06520
Actively Recruiting
5
Xencor Investigative Site
Jacksonville, Florida, United States, 32224
Actively Recruiting
6
Xencor Investigative Site
Atlanta, Georgia, United States, 30322
Actively Recruiting
7
Xencor Investigative Site
Chicago, Illinois, United States, 60611
Actively Recruiting
8
Xencor Investigative Site
Chicago, Illinois, United States, 60637
Actively Recruiting
9
Xencor Investigative Site
Louisville, Kentucky, United States, 40207
Actively Recruiting
10
Xencor Investigative Site
Rochester, Minnesota, United States, 55905
Actively Recruiting
11
Xencor Investigative Site
New Brunswick, New Jersey, United States, 088901
Actively Recruiting
12
Xencor Investigative Site
New York, New York, United States, 10032
Actively Recruiting
13
Xencor Investigative Site
New York, New York, United States, 10065
Actively Recruiting
14
Xencor Investigative Site
Charlotte, North Carolina, United States, 28777
Actively Recruiting
15
Xencor Investigative Site
Durham, North Carolina, United States, 27710
Actively Recruiting
16
Xencor Investigative Site
Cincinnati, Ohio, United States, 45267
Actively Recruiting
17
Xencor Investigative Site
Columbus, Ohio, United States, 43210
Actively Recruiting
18
Xencor Investigative Site
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
19
Xencor Investigative Site
Nashville, Tennessee, United States, 37203
Actively Recruiting
20
Xencor Investigative Site
Seattle, Washington, United States, 98109
Actively Recruiting
21
Xencor Investigative Site
Villejuif, France, 94805
Actively Recruiting
22
Xencor Investigative Site
Madrid, Spain, 28050
Actively Recruiting
23
Xencor Investigative Site
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
Actively Recruiting
Research Team
C
Chet Bohac, MD
CONTACT
L
Lisa Finnigan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here